Followers | 0 |
Posts | 678 |
Boards Moderated | 0 |
Alias Born | 03/25/2012 |
Thursday, October 25, 2012 6:08:46 PM
Recent LXRX News
- Form 8-K - Current report • Edgar (US Regulatory) • 10/16/2024 08:37:25 PM
- Lexicon Announces Exclusive Licensing Agreement With Viatris for Sotagliflozin in All Markets Outside of the U.S. and Europe • GlobeNewswire Inc. • 10/16/2024 08:35:00 PM
- Viatris Announces Exclusive Licensing Agreement with Lexicon Pharmaceuticals for Sotagliflozin in all Markets Outside of the U.S. and Europe • PR Newswire (US) • 10/16/2024 08:34:00 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 10/07/2024 08:58:38 PM
- Lexicon to Present Phase 3 Trial Design for Sotagliflozin in Hypertrophic Cardiomyopathy (HCM) at Upcoming Medical Congress • GlobeNewswire Inc. • 09/27/2024 12:00:00 PM
- Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer • GlobeNewswire Inc. • 09/16/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 10:51:46 AM
- New Secondary Analysis of Phase 3 Data Demonstrates Sotagliflozin Improves Time-In-Range (TIR) and Several Parameters of Glucose Control and Variability in Basal Insulin-Treated Type 2 Diabetes • GlobeNewswire Inc. • 09/10/2024 12:00:00 PM
- Lexicon Pharmaceuticals to Participate in Upcoming September Investor Conferences • GlobeNewswire Inc. • 09/03/2024 08:00:00 PM
- New Secondary Analysis of Phase 3 Data Demonstrates that INPEFA® (Sotagliflozin) Benefited Heart Failure Patients Regardless of Diabetes Duration • GlobeNewswire Inc. • 09/03/2024 12:00:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/15/2024 08:47:50 PM
- Lexicon Pharmaceuticals Announces Strategic Repositioning to Drive Value and Growth of Commercial Portfolio • GlobeNewswire Inc. • 08/13/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 12:40:16 PM
- Efficacy and Safety Data of Sotagliflozin in Patients with Type 1 Diabetes and Chronic Kidney Disease Among Three Lexicon-Sponsored Presentations at the 2024 Annual Conference of the Association of Diabetes Care & Education Specialists • GlobeNewswire Inc. • 08/07/2024 12:00:00 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 08/02/2024 01:37:54 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/02/2024 11:06:49 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:05:23 PM
- Lexicon Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/01/2024 08:00:00 PM
- Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend] • Edgar (US Regulatory) • 07/29/2024 09:44:55 PM
- Lexicon Pharmaceuticals to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 1, 2024 • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Lexicon Pharmaceuticals Receives December 20, 2024 PDUFA Goal Date for Sotagliflozin Type 1 Diabetes NDA Resubmission • GlobeNewswire Inc. • 07/16/2024 12:00:00 PM
- New Published Data Highlights Potential Cost-Savings of INPEFA® (sotagliflozin) for Heart Failure • GlobeNewswire Inc. • 07/15/2024 12:00:00 PM
SANUWAVE Announces Reverse Stock Split, Note and Warrant Exchange, and PIPE Offering • SNWV • Oct 18, 2024 9:31 AM
Vocodia Addresses Recent Stock Price Movement and Future Strategic Partnerships • VHAI • Oct 18, 2024 9:00 AM
Mass Megawatts Announces the Start of an Online Discount Solar Energy Equipment Business with Revenue Recognized for the First Time Since Year 2010 in this Fiscal Quarter • MMMW • Oct 18, 2024 7:32 AM
Unitronix Corp Advances DeFi Innovation with Tokenized Real-World Assets Integration • UTRX • Oct 17, 2024 7:38 AM
Mass Megawatts Commences Solar Energy Sales Efforts • MMMW • Oct 16, 2024 7:45 AM
SANUWAVE Health Announces 1-For-375 Reverse Stock Split • SNWV • Oct 16, 2024 7:40 AM